Agranulocytosis and liver damage associated with pyrazinobutazone with evidence for an immunological mechanism.

Abstract

Agranulocytosis and liver injury is described in a patient with Reiter's syndrome of 3 years duration who received pyrazinobutazone for 6 weeks before the development of the clinical picture reported. Other causes of agranulocytosis and hepatic damage were excluded and a lymphocyte transformation test to the drug revealed significant lymphocyte proliferation in response to the drug. This suggests a hypersensitivity reaction as the mechanism for this previously unrecognized association of adverse effects to pyrazinobutazone.

• Authors: V A Maria, J A da Silva, R M Victorino
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 16 Issue 11 Pg. 1484-5 (Nov 1989) ISSN: 0315-162X [Print] Canada
• PMID: 2600947 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• pyrazinobutazone
• Phenylbutazone

Topics

• Adult
• Agranulocytosis (chemically induced)
• Anti-Inflammatory Agents, Non-Steroidal (adverse effects, therapeutic use)
• Arthritis, Reactive (drug therapy)
• Drug Hypersensitivity (etiology)
• Hepatomegaly (chemically induced)
• Humans
• Lymphocyte Activation (drug effects)
• Male
• Phenylbutazone (adverse effects, analogs & derivatives, therapeutic use)